Quarterly report pursuant to Section 13 or 15(d)

Balance Sheets (Unaudited)

v2.4.0.6
Balance Sheets (Unaudited) (USD $)
Jun. 30, 2012
Sep. 30, 2011
Balance Sheets    
Cash $ 1,445,276 $ 469,786
Prepaid expenses 463,433 37,611
Grant receivable    179,358
Other current assets    5,000
Total Current Assets 1,908,709 691,755
EQUIPMENT, net 45,475 19,164
Patent costs, net 643,261 701,927
TOTAL ASSETS 2,597,445 1,412,846
Accounts payable and accrued expenses 292,040 301,055
Notes payable 44,355  
Derivative liabilities 2,084,021 5,893,544
Total Current Liabilities 2,420,416 6,194,599
TOTAL LIABILITIES 2,420,416 6,194,599
Preferred stock, Series B; 6,000,000 shares authorized, at $0.0001 par value, 5,583,336 and 5,583,336 shares issued and outstanding, respectively 558 558
Common stock; 180,000,000 shares authorized, at $0.0001 par value, 47,144,253 and 39,702,580 shares issued and outstanding, respectively 4,714 3,970
Additional paid-in capital 30,585,444 22,289,231
Stock subscription receivable (1,815,842)   
Accumulated deficit (21,628,748) (21,628,748)
Deficit accumulated during the development stage (6,969,097) (5,446,764)
Total Stockholders' Equity (Deficit) 177,029 (4,781,753)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) $ 2,597,445 $ 1,412,846